HOME >> MEDICINE >> NEWS
ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia

ausing bone marrow dysfunction and enlargement of the lymph nodes, liver and spleen. Standard front line therapy consists of alkylating agent based drug regimens. Fludarabine is the only approved drug for the treatment of patients who have failed alkylating agents. No approved therapy is available for patients who fail fludarabine therapy.

CAMPATH appears to work in CLL by depleting malignant CLL cells, which bear the CD52 antigen. CAMPATH is a humanized monoclonal antibody which is directed against the CD52 antigen found on normal and malignant lymphocytes, on normal macrophages and monocytes, but has not been detected on hematopoietic stem cells.

CAMPATH therapy is associated with significant lymphopenia. The lymphopenia resolves in some, but not all, patients over weeks to months after cessation of CAMPATH therapy.

"Early studies suggested the promise of CAMPATH. This study appears to confirm the decision to submit a BLA to the FDA," said Kanti R. Rai, M.D., Chief, Division Hematology-Oncology, Long Island Jewish Medical Center. "CAMPATH may very well become the next new and promising monoclonal antibody therapy for patients with cancer. For our patients with CLL, CAMPATH may change the expectation from one of relentlessly progressive deterioration on palliative therapies to the hope of extended survival," said Dr. Rai, who is also one of the trial's principal investigators and an internationally recognized expert in CLL.

ILEX and LeukoSite are developing CAMPATH through a joint venture that was established in May 1997. Clinical trials in the treatment of non-Hodgkin?s lymphoma, CLL, and other malignancies expressing CD52 are being planned.

"CAMPATH is the most advanced of ILEX's nine compounds and we are anxious to make it available to patients," said Richard L. Love, president and chief executive officer of ILEX.

ILEX Oncology, Inc. is a drug development company focused exclusively on accelerated development of drugs fo
'"/>

Contact: Deborah Sibley, ILEX Oncology
210-949-8287
Porter Novelli
12-Jun-1999


Page: 1 2 3 4 5

Related medicine news :

1. The 23rd Congress of the European Society for Therapeutic Radiology and Oncology (ESTRO)
2. Oncology Nursing Society honors Fox Chase Cancer Center nurse with Radiation Therapy Nursing Award
3. The Lancet Oncology (TLO)
4. The Lancet Oncology press release
5. The Lancet Oncology (TLO) and the Lancet Infectious Diseases (TLID)
6. The Lancet Oncology (TLO) June 2002
7. The Lancet Oncology (TLO) and The Lancet Infectious Diseases (TLID)
8. The Lancet Oncology and The Lancet Infectious Diseases
9. V. Craig Jordan Will Present Results Of Raloxifene Breast Cancer Study At American Society For Clinical Oncology Meeting
10. First UK cases of previously rare disease reported in gay men
11. Health care report cards may increase racial/ethnic disparities in bypass operations

Post Your Comments:
(Date:2/27/2015)... Lyophilization has important applications in the pharmaceutical ... process to stabilize, store and increase the shelf life ... vaccines, antibodies, proteins, enzymes, hormones, blood plasma and ... freeze drying market was valued at $1,969.7 million in ... by 2019 at a CAGR of 6.2% during the ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 BaliniSports is ... with the online fitness social platform FITMOO. The collaboration ... products and holistic philosophy behind BaliniSports. Users of FITMOO ... an intimate way and discover apparel that will enhance ... that uses environmentally friendly and socially conscious methods to ...
(Date:2/27/2015)... Ticket Down announces that Ed Sheeran ... of 2015. Tickets for his tour have been a ... record pace. , Ed Sheeran 2015 Tour Dates: ... Wednesday, May 6, 2015 , 5/7/15, Ed Sheeran Tickets, Grand ... 2015 , 5/9/15, Ed Sheeran Tickets, Tulsa, OK BOK Center, ...
(Date:2/27/2015)... February 27, 2015 The decision to relocate ... newer facilities and to make camp more accessible to campers ... for a Contact Football Camp. The fields are in premier ... the country,” states Mike de Surville, vice president of US ... comprised of experienced coaches with the passion to create a ...
(Date:2/27/2015)... 2015 The report “Polycystic Ovarian ... information on the therapeutic development for polycystic ovarian ... which a woman's hormones are out of balance. ... teenage girls and young women. The cause of ... R&D pipelines by identifying new targets and MOAs ...
Breaking Medicine News(10 mins):Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Lyophilization Equipment Market worth $2,655.9 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:BaliniSports Announces Collaboration with FITMOO 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 2Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 3Health News:Ed Sheeran Tickets at the Hollywood Bowl, Verizon Theatre, The Mann Center, Darlings Waterfront Pavilion, Moda Center, BOK Center, Consol Energy & Red Rocks Now On Sale 4Health News:US Sports Camps Football Camps Announce New Contact Football Camp Northeast Location 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 2Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 3Health News:Polycystic Ovarian Syndrome Therapeutics Pipeline Market H1 2015 Review Report Now Available at RnRMarketResearch.com 4
(Date:2/26/2015)... Calif. , Feb. 26, 2015  BD Life ... Company) (NYSE: BDX ), a leading ... innovative company focused on enabling high-resolution biology, today ... unique solutions for highly multiplexed cell isolation and ... are promoting BD,s powerful BD FACS™ single-cell sorting ...
(Date:2/26/2015)... Feb. 26, 2015  Spring Bank Pharmaceuticals, Inc., ... the treatment of virus infections, today announced that ... appointed Vice President of Finance, a newly created ... and administrative activities, including financial planning and reporting, ... Douglas J. Jensen , President and CEO. ...
(Date:2/26/2015)... , Feb. 26, 2015 Integrity Applications, Inc. ... GlucoTrack ® model DF-F, a noninvasive  device that tracks ... Heinemann , Ph.D., will head its new scientific advisory ... in the field of Diabetes research, monitoring and treatment. ... has been Chief Executive Officer and Head, Business Development ...
Breaking Medicine Technology:BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3Jonathan P. Freve, CPA, Joins Spring Bank Pharmaceuticals as Vice President of Finance 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4
Cached News: